{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:58:56Z","timestamp":1790240336118,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"DOI":"10.1007\/s11926-026-01235-x","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:59:12Z","timestamp":1790236752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Why Do Some Therapies Work While Others Fail? Mechanisms of Response and Emerging Treatments in axial Spondyloarthritis: 2026 SPARTAN Annual Meeting Proceedings"],"prefix":"10.1007","volume":"28","author":[{"given":"Brooke J","family":"Rutledge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4258-1603","authenticated-orcid":false,"given":"Akihiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"1235_CR1","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, \u00d8stergaard M, Wei JC-C, Sieper J, J\u00e4rvinen P, Tam L-S, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77:1295\u2013302.","journal-title":"Ann Rheum Dis"},{"key":"1235_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis. Arthritis Rheumatol United States. 2019;71:258\u201370.","journal-title":"Arthritis Rheumatol United States"},{"key":"1235_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper J, Porter-Brown B, Thompson L, Harari O, Dougados M. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73:95\u2013100.","journal-title":"Ann Rheum Dis"},{"key":"1235_CR4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1136\/ard.2004.023176","volume":"64","author":"H Haibel","year":"2005","unstructured":"Haibel H, Rudwaleit M, Listing J, Sieper J. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis. 2005;64:296\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1235_CR5","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.1016\/S2665-9913(24)00099-7","volume":"6","author":"C Worth","year":"2024","unstructured":"Worth C, Al-Mossawi MH, Macdonald J, Fisher BA, Chan A, Sengupta R, et al. Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol. 2024;6:e537\u201345.","journal-title":"Lancet Rheumatol"},{"key":"1235_CR6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/ng.513","volume":"42","author":"JD Reveille","year":"2010","unstructured":"Reveille JD, Sims A-M, Danoy P, Evans DM, Leo P, Pointon JJ, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010;42:123\u20137.","journal-title":"Nat Genet"},{"key":"1235_CR7","first-page":"1069","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3\u2009+\u2009CD4-CD8- entheseal resident T cells. Nat Med United States. 2012;18:1069\u201376.","journal-title":"Nat Med United States"},{"key":"1235_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11926-021-00995-y","volume":"23","author":"A Nakamura","year":"2021","unstructured":"Nakamura A, Haroon N. Recent Updates in the Immunopathology of Type 3 Immunity-Mediated Enthesitis. Curr Rheumatol Rep United States. 2021;23:31.","journal-title":"Curr Rheumatol Rep United States"},{"key":"1235_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11926-024-01176-3","volume":"27","author":"P Remalante-Rayco","year":"2025","unstructured":"Remalante-Rayco P, Nakamura A. Year in Review: Novel Insights in the Pathogenesis of Spondyloarthritis \u2013 SPARTAN 2024 Annual Meeting Proceedings. Curr Rheumatol Rep. 2025;27:9.","journal-title":"Curr Rheumatol Rep"},{"key":"1235_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11926-025-01194-9","volume":"27","author":"B Wu","year":"2025","unstructured":"Wu B, Tang A, Nakamura A. Recent Advances in the Immunopathology of Axial Spondyloarthritis: with and without HLA-B27. Curr Rheumatol Rep. 2025;27:27.","journal-title":"Curr Rheumatol Rep"},{"key":"1235_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/mr\/roab057","volume":"32","author":"M Kusuda","year":"2022","unstructured":"Kusuda M, Haroon N, Nakamura A. Complexity of enthesitis and new bone formation in ankylosing spondylitis: current understanding of the immunopathology and therapeutic approaches. Mod Rheumatol. 2022;32:484\u201392.","journal-title":"Mod Rheumatol"},{"key":"1235_CR12","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.ard.2025.04.018","volume":"84","author":"F Liu","year":"2025","unstructured":"Liu F, Shi H, Turner JD, Anscombe R, Li J, Sekine T, et al. CD4\u2009+\u2009tissue-resident memory Th17 cells are a major source of IL-17A in Spondyloarthritis synovial tissue. Ann Rheum Dis. 2025;84:1151\u201363.","journal-title":"Ann Rheum Dis"},{"key":"1235_CR13","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.2024.20917","volume":"333","author":"M Bittar","year":"2025","unstructured":"Bittar M, Deodhar A. Axial Spondyloarthritis: A Review. JAMA. 2025;333:408\u201320.","journal-title":"JAMA"},{"key":"1235_CR14","doi-asserted-by":"publisher","first-page":"1658325","DOI":"10.3389\/fimmu.2025.1658325","volume":"16","author":"N McDermott","year":"2025","unstructured":"McDermott N, Altaie A, Macleod T, Bridgewood C, Loughenbury P, Dunsmuir R, et al. Human spinal enthesis comparative biology of IL-17F and IL-17A reveals greater T-cell IL-17F induction and IL-23 regulation. Front Immunol. 2025;16:1658325.","journal-title":"Front Immunol"},{"key":"1235_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00281-020-00833-w","volume":"43","author":"A Nakamura","year":"2021","unstructured":"Nakamura A, Boroojeni SF, Haroon N. Aberrant antigen processing and presentation: Key pathogenic factors leading to immune activation in Ankylosing spondylitis. Semin Immunopathol Ger. 2021;43:245\u201353.","journal-title":"Semin Immunopathol Ger"},{"key":"1235_CR16","doi-asserted-by":"crossref","unstructured":"Martini V, Silvestri Y, Ciurea A, M\u00f6ller B, Danelon G, Flamigni F, et al. Patients with ankylosing spondylitis present a distinct CD8 T cell subset with osteogenic and cytotoxic potential. RMD Open. 2024;10:e003926.","DOI":"10.1136\/rmdopen-2023-003926"},{"key":"1235_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/nrd1441","volume":"3","author":"JJ O\u2019Shea","year":"2004","unstructured":"O\u2019Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK\/STAT pathway. Nat Rev Drug Discov. 2004;3:555\u201364.","journal-title":"Nat Rev Drug Discov"},{"key":"1235_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","volume":"20","author":"A Virtanen","year":"2024","unstructured":"Virtanen A, Spinelli FR, Telliez JB, O\u2019Shea JJ, Silvennoinen O, Gadina M. JAK inhibitor selectivity: new opportunities, better drugs? Nat Rev Rheumatol. 2024;20:649\u201365.","journal-title":"Nat Rev Rheumatol"},{"key":"1235_CR19","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1038\/s41467-025-60445-6","volume":"16","author":"W Song","year":"2025","unstructured":"Song W, Lee EE, Park S, Choi B, Kim M-G, Ban SY, et al. Type 1 interferon signature and allograft inflammatory factor-1 contribute to refractoriness to TNF inhibition in ankylosing spondylitis. Nat Commun. 2025;16:5531.","journal-title":"Nat Commun"},{"key":"1235_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.42974","volume":"77","author":"A Pacheco","year":"2025","unstructured":"Pacheco A, Maguire S, Qaiyum Z, Tang M, Bridger A, Lim M, et al. Enhanced Type 1 Interferon Signature in Axial Spondyloarthritis Patients Unresponsive to Secukinumab Treatment. Arthritis Rheumatol. 2025;77:34\u201346.","journal-title":"Arthritis Rheumatol"},{"key":"1235_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1136\/ard.2008.107102","volume":"69","author":"G Nocturne","year":"2010","unstructured":"Nocturne G, Dougados M, Constantin A, Richez C, Sellam J, Simon A, et al. Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry. Ann Rheum Dis. 2010;69:471\u20132.","journal-title":"Ann Rheum Dis"},{"key":"1235_CR22","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1136\/ard.2010.145946","volume":"70","author":"I-H Song","year":"2011","unstructured":"Song I-H, Heldmann F, Rudwaleit M, Haibel H, Weiss A, Braun J, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011;70:1108\u201310.","journal-title":"Ann Rheum Dis"},{"key":"1235_CR23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/art.38291","volume":"66","author":"JA Smith","year":"2014","unstructured":"Smith JA, Colbert RA, Review. The interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol. 2014;66:231\u201341.","journal-title":"Arthritis Rheumatol"},{"key":"1235_CR24","doi-asserted-by":"publisher","first-page":"eabg1210","DOI":"10.1126\/scitranslmed.abg1210","volume":"13","author":"A Nakamura","year":"2021","unstructured":"Nakamura A, Zeng F, Nakamura S, Reid KT, Gracey E, Lim M, et al. Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease. Sci Transl Med. 2021;13:eabg1210.","journal-title":"Sci Transl Med"},{"key":"1235_CR25","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41423-024-01183-5","volume":"21","author":"A Nakamura","year":"2024","unstructured":"Nakamura A, Jo S, Nakamura S, Aparnathi MK, Boroojeni SF, Korshko M, et al. HIF-1\u03b1 and MIF enhance neutrophil-driven type 3 immunity and chondrogenesis in a murine spondyloarthritis model. Cell Mol Immunol. 2024;21:770\u201386.","journal-title":"Cell Mol Immunol"},{"key":"1235_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","volume":"81","author":"A \u00d6st\u00f6r","year":"2022","unstructured":"\u00d6st\u00f6r A, Van den Bosch F, Papp K, Asnal C, Blanco R, Aelion J, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. Ann Rheum Dis. 2022;81:351\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1235_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa2314585","volume":"391","author":"L Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L, Chapman JC, Colombel J-F, Caprioli F, D\u2019Haens G, Ferrante M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn\u2019s Disease. N Engl J Med. 2024;391:213\u201323.","journal-title":"N Engl J Med"},{"key":"1235_CR28","doi-asserted-by":"publisher","unstructured":"McGonagle D, Watad A, Sharif K, Bridgewood C. Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis. Front Immunol. 2021;12. https:\/\/doi.org\/10.3389\/fimmu.2021.614255.","DOI":"10.3389\/fimmu.2021.614255"},{"key":"1235_CR29","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S2665-9913(22)00334-4","volume":"5","author":"T Macleod","year":"2023","unstructured":"Macleod T, Bridgewood C, McGonagle D. Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders. Lancet Rheumatol. 2023;5:e47\u201357.","journal-title":"Lancet Rheumatol"},{"key":"1235_CR30","doi-asserted-by":"crossref","unstructured":"Cuthbert RJ, Watad A, Fragkakis EM, Dunsmuir R, Loughenbury P, Khan A et al. Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression. Ann Rheum Dis. 2019;78:1559-1565.","DOI":"10.1136\/annrheumdis-2019-215210"},{"key":"1235_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.47360\/1995-4484-2024-65-80","volume":"62","author":"EL Nasonov","year":"2024","unstructured":"Nasonov EL, Mazurov VI, Lila AM, Dubinina TV, Gaydukova IZ, Lapshina SA, et al. Effectiveness and safety of BCD180, anti-TRBV9\u2009+\u2009T-lymphocytes monoclonal antibody in patients with active radiographic axial spondyloarthritis: 36-week results of double-blind randomized placebo-controlled phase II clinical study ELEFTA. Rheumatol Sci Pract. 2024;62:65\u201380.","journal-title":"Rheumatol Sci Pract"},{"key":"1235_CR32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41584-025-01286-x","volume":"21","author":"JD Reveille","year":"2025","unstructured":"Reveille JD, Eder L, Ziade N, Sampaio-Barros PD, Kim T-H, Akko\u00e7 N, et al. Global epidemiology of spondyloarthritis. Nat Rev Rheumatol. 2025;21:580\u201398.","journal-title":"Nat Rev Rheumatol"},{"key":"1235_CR33","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1038\/s41591-023-02613-z","volume":"29","author":"OV Britanova","year":"2023","unstructured":"Britanova OV, Lupyr KR, Staroverov DB, Shagina IA, Aleksandrov AA, Ustyugov YY, et al. Targeted depletion of TRBV9\u2009+\u2009T cells as immunotherapy in a patient with ankylosing spondylitis. Nat Med. 2023;29:2731\u20136.","journal-title":"Nat Med"},{"issue":"16","key":"1235_CR34","doi-asserted-by":"publisher","first-page":"e174776","DOI":"10.1172\/jci.insight.174776","volume":"18","author":"MA Paley","year":"2024","unstructured":"Paley MA, Yang X, Hassman LM, Penkava F, Garner LI, Paley GL, et al. Mucosal signatures of pathogenic T cells in HLA-B*27\u2009+\u2009anterior uveitis and axial spondyloarthritis. JCI Insight. 2024;18(16):e174776.","journal-title":"JCI Insight"},{"key":"1235_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ard.2025.05.414","volume":"84","author":"S Glavaris","year":"2025","unstructured":"Glavaris S, Pearlman A, Liu J, Ge J, Xia Y, Kaeo KK, et al. POS0017\u2005Bispecific T Cell-Engaging Antibodies to Target TRBV9\u2009+\u2009Autoreactive T Cells in Axial Spondyloarthritis. Ann Rheum Dis. 2025;84:334\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1235_CR36","doi-asserted-by":"publisher","first-page":"104752","DOI":"10.1016\/j.critrevonc.2025.104752","volume":"212","author":"L Han","year":"2025","unstructured":"Han L, Wang K, Jiang Z, Guo X, Yu J. Recent development in bispecific antibody immunotherapy for hematological malignancies. Crit Rev Oncol Hematol. 2025;212:104752.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1235_CR37","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-026-04238-4","volume":"32","author":"C D\u00fcsing","year":"2026","unstructured":"D\u00fcsing C, Gy\u00f6rfi A-H, St\u00fctz AN, Lahu L-M, Deicher FS, Li Y-N, et al. Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases. Nat Med. 2026;32:1530\u201342.","journal-title":"Nat Med"},{"key":"1235_CR38","doi-asserted-by":"publisher","first-page":"114075","DOI":"10.1016\/j.ejca.2024.114075","volume":"205","author":"A G\u00e9raud","year":"2024","unstructured":"G\u00e9raud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, et al. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review. Eur J Cancer. 2024;205:114075.","journal-title":"Eur J Cancer"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-026-01235-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-026-01235-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:59:15Z","timestamp":1790236755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-026-01235-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1235"],"URL":"https:\/\/doi.org\/10.1007\/s11926-026-01235-x","relation":{},"ISSN":["1534-6307"],"issn-type":[{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"13 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not include any research involving human or animal subjects conducted by the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.N. has received consultant fees and\/or speaking honoraria from Abbvie, Amgen, AstraZeneca, Celltrion, Fresenius Kabi Canada, JAMP Pharma, Novartis, UCB Canada, UCB Japan. Other authors do not have any disclosures.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27"}}